Physician profile
Daniel Good
NPI 1942316682
$2,055.93
in general payments reported to CMS, 2019-2025
25 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $203 · 2021: $208 · 2022: $710 · 2023: $334 · 2024: $326 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $338.69 | 2022-2025 | Rocklatan, Clareon, Tryptyr |
| Abbvie INC. | $288.55 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $240.02 | 2020-2022 | |
| Sight Sciences, INC. | $218.65 | 2020-2022 | |
| Apellis Pharmaceuticals, INC. | $125.00 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $123.62 | 2022 | |
| Oyster Point Pharma, INC. | $109.26 | 2022-2025 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $89.54 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $77.67 | 2024-2025 | Vyzulta, Miebo |
| Novartis Pharmaceuticals Corporation | $68.90 | 2021-2022 | |
| Harrow Eye, LLC | $49.46 | 2024 | Vevye, Iheezo, Triesence |
| Eyevance Pharmaceuticals LLC | $43.55 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $38.01 | 2025 | Xdemvy |
| Horizon Therapeutics Plc | $36.07 | 2019-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $26.08 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $24.25 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.91 | 2021 | |
| Dompe US, INC. | $21.67 | 2024 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $20.39 | 2024 | |
| Biotissue Holdings INC. | $19.81 | 2024 | |
| Notal Vision, INC. | $18.03 | 2024 | Foresee Home |
| Sun Pharmaceutical Industries INC. | $16.66 | 2021 | |
| Genentech USA, INC. | $14.03 | 2022 | |
| Rayner Intraocular Lenses Limited | $12.92 | 2023 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Integra Lifesciences Corporation | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Good listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.